The NHS Confederation report Unlocking Prevention in Integrated Care Systems(1) highlights the burden of proving for value for money and return on investment (ROI). Where reduced mobility and risk of falls are issues, there is a proven solution.
A solution that can help reduce the 43,000 patients hospitalised as a result of falls on stairs each year (RoSPA).
AAT GB, the #1 in stairclimbing wheelchairs, says its unique re-issue capability delivers guaranteed ROI- 12 years of patient care & support for less than the cost of 2 standard hospital bed days/year(2).
Its market-leading position means it has the sheer number of stairclimbers available to NHS Trusts and local authorities to efficiently effect re-issue, whereby when one patient no longer needs the equipment, it can be re-prescribed to another.
Importantly, the process takes days, as opposed to the weeks, months of alternative stairway access/inter-floor options. The portable, mobile S-Max Sella requires no structural survey nor installation. It can be funded via conventional equipment channels without the need for Disabled Facilities Grant application.
The speed with which the intervention can be deployed also means the risk of falling on steps or stairs is efficiently managed, fulfilling the shift towards prevention and community based integrated care.
To further facilitate ROI, AAT offers a complete support package covering patient assessment, re-issue, and stock management.
“Optimisation of the stairclimber stock within the care services clearly demonstrates value for money and effective return on investment,” says Peter Wingrave AAT Director. “Importantly, we have a 20+ years’ track record of effecting safe stairway transfer and are increasingly becoming the front line option to prevent falls on stairs and potential hospital admission. Our stairclimbers also help people remain in their homes, without the need for either moving into a care home, the provision of home care to support inter-level movement, the cost and disruption to daily life of a more permanent fixture or adaptation, or moving home.”
Details of the S-Max and AAT’s service can be found @ www.aatgb.com.
ENDS
References:
(1)https://www.nhsconfed.org/system/files/2024-10/Unlocking-prevention-in-ICSs-Report_0.pdf
(2)capital cost of an S-Max Sella including re-issue to three patients over lifespan of 12 years = £637 pa. Cost/hospital bed/day £345:
(3)(https://questions-statements.parliament.uk/written-questions/detail/2023-03-14/165361)
